AXA Framlington Biotech Fund - Z Acc
SpecialistPricing frequency
Daily
Dealing cut off time
11:00
Type
Unit Trust
Yield
–
NAV
638.40p
Income frequency
Semi-annually
Ongoing charge
0.82%
Latest actual NAV date
30-10-2026
ISIN
GB00B784NS11
UCITS
Yes
This fund can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPPand can be used with Regular investment
Before investing please read:
Growth of 10k
Asset allocation
Top 10 holdings
| Holdings 31/07/2026 | % of assets |
|---|---|
| Vertex Pharmaceuticals Inc | 7.43 |
| Amgen Inc | 6.84 |
| Regeneron Pharmaceuticals Inc | 6.83 |
| Gilead Sciences Inc | 5.90 |
| argenx SE ADR | 4.71 |
| Revolution Medicines Inc Ordinary Shares | 3.91 |
| United Therapeutics Corp | 3.55 |
| Insmed Inc | 3.25 |
| Mirum Pharmaceuticals Inc | 3.03 |
| Alkermes PLC | 2.39 |
Investment objective
The aim of this Fund is to provide long-term capital growth over a period of 5 years or more. The Fund invests in shares of listed companies, principally in the biotechnology, genomic and medical research industry, which the Manager believes will provide above-average returns. The Fund invests in companies of any size which can be based anywhere in the world, albeit the Fund tends to be biased towards the US as this is where the majority of biotechnology companies are based. The Manager selects shares based upon analysis of a company’s financial status, quality of its management, expected profitability and prospects for growth.